Channing Capital Management LLC Sells 11,279 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Channing Capital Management LLC has reduced its stake in Edwards Lifesciences Corporation by 9.0%, now holding $8.27 million in shares after selling 11,279 shares during the first quarter.
• Several institutional investors, including Global X Japan Co. Ltd. and Tradewinds Capital Management LLC, have significantly increased their holdings in Edwards Lifesciences, indicating growing institutional interest.
• Analysts have raised their price targets for Edwards Lifesciences, with Morgan Stanley setting a target of $81.00 and Stifel Nicolaus targeting $95.00, reflecting confidence in the company's performance and outlook.

Channing Capital Management LLC reduced its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 9.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 114,092 shares of the medical research company's stock after selling 11,279 shares during the period. Channing Capital Management LLC's holdings in Edwards Lifesciences were worth $8,269,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Jennison Associates LLC grew its stake in Edwards Lifesciences by 34.3% during the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock worth $731,036,000 after purchasing an additional 2,576,383 shares during the period. Brown Advisory Inc. lifted its stake in Edwards Lifesciences by 7.6% in the fourth quarter. Brown Advisory Inc. now owns 8,155,355 shares of the medical research company's stock valued at $603,741,000 after buying an additional 575,699 shares during the period. Deutsche Bank AG boosted its holdings in shares of Edwards Lifesciences by 10.4% during the 4th quarter. Deutsche Bank AG now owns 6,903,202 shares of the medical research company's stock worth $511,044,000 after buying an additional 652,923 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Edwards Lifesciences by 8.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,519,257 shares of the medical research company's stock worth $482,621,000 after buying an additional 513,468 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Edwards Lifesciences by 21.8% in the 4th quarter. Northern Trust Corp now owns 6,505,227 shares of the medical research company's stock valued at $481,582,000 after acquiring an additional 1,165,845 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the transaction, the insider owned 206,900 shares in the company, valued at approximately $15,565,087. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 24,584 shares of company stock valued at $1,897,762 over the last 90 days. Insiders own 1.29% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on EW. Canaccord Genuity Group boosted their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a research report on Friday, July 25th. BTIG Research upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price objective on the stock in a report on Tuesday, July 29th. Royal Bank Of Canada increased their price objective on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Piper Sandler raised their target price on Edwards Lifesciences from $83.00 to $90.00 and gave the company an "overweight" rating in a research note on Friday, July 25th. Finally, William Blair raised Edwards Lifesciences to a "strong-buy" rating in a research report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $85.90.

Edwards Lifesciences Stock Up 0.7%

Shares of NYSE:EW traded up $0.5950 during midday trading on Friday, hitting $81.7550. 3,076,141 shares of the company's stock were exchanged, compared to its average volume of 4,824,093. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. Edwards Lifesciences Corporation has a 12 month low of $64.00 and a 12 month high of $83.00. The company has a market cap of $48.00 billion, a PE ratio of 11.76, a price-to-earnings-growth ratio of 3.95 and a beta of 1.08. The stock has a 50 day moving average price of $77.58 and a 200-day moving average price of $74.69.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.